Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated inflammatory demyelinationdisease among children

doi:10.3877/cma.j.issn.1673-5250.2021.03.012

Objective

To investigate clinical manifestations, imaging features, treatment and prognosis of children with myelin oligodendrocyte glycoprotein (MOG) antibody-associated inflammatory demyelination disease (IDD).

Methods

Seven children with MOG autoantibody-associated IDD diagnosed at the Department of Pediatrics, Sun Yat-Sen Memorial Hospital of Sun Yat-sen University from June 1, 2014 to September 30, 2020 were selected as research subjects, including 2 girls and 5 boys with an average age of 8.3 years old. The clinical features, imaging findings, treatment and prognosis of 7 children with MOG antibody-related IDD were analyzed retrospectively. The procedures followed in this study were in line with the requirements of the World Medical Association Declaration of Helsinki revised in 2013.

Results

①At initial diagnosis, the 7 cases were misdiagnosed as acute disseminated encephalomyelitis (ADEM, 2 cases), optic neuritis (ON, 2 cases), multiple sclerosis (MS, 1 case), meningitis (1 case) and autoimmune encephalitis (AE, 1 case). Among them, the younger children presented with ON symptoms, while the older children presented with ADEM symptoms. ②Among the 7 cases, 2 cases had elevated white blood cell count (WBC) and protein level in cerebrospinal fluid, 6 cases with intracranial pressure >200 mmH₂O (1 mmH₂O=0.098 1 kPa). All the children were positive for MOG antibody in peripheral blood, 6 cases were positive for MOG antibody in cerebrospinal fluid, and 1 case was positive for anti-CASPR-2 antibody in peripheral blood. ③Among the 7 children, the results of laboratory examination showed that WBC increased in 2 cases, and C-reaction protein (CRP) was positive and erythrocyte sedimentation rate (ESR) increased in 1 case in peripheral blood. All the children′s peripheral blood MOG antibody were positive, and 1 child′s peripheral blood anti-CASPR-2 antibody was positive.④The results of imaging examination showed that the lesions involved around the lateral ventricle in 5 cases, basal ganglia in 3 cases, thalamus, spinal cord and optic nerve in 2 cases, brainstem in 1 case and medulla oblongata in 1 case, meningeal enhancement in 1 case. The lesion diameters of 7 cases were larger than 2 cm. In addition, a clear boundary of lesions could be found in 3 children whose ages were more than 5 years old.⑤In the acute phase, 1 child was treated with methylprednisolone [10-30 mg/ (kg·d), dose halved every 3 days] and intravenous immunoglobulin (IVIG) [2 g/(kg·d)×1 d], and 6 children were treated with dexamethasone [initial dose of 0.5 mg/(kg·d) and IVIG 0.4 g/(kg·d)×5 d]. During the maintenance period, all of them were treated with oral prednisone, and 5 of them were treated with IVIG (2 g/kg) every month. 2 recurrent children were treated with methylprednisolone and IVIG again, and 1 of them was treated with rituximab (375 mg/m², once a week for 4 times). After treatment, 5 children recovered completely and 2 children partially recovered. The average annualized relapse rate (ARR) was 0.4 times per year.

Conclusions

MOG antibody-associated IDD has various clinical manifestations and is easy to be misdiagnosed in the early stage. MOG antibody and AE-related antibody can exist at the same time, and most of the imaging findings are multifocal lesions. Although MOG antibody-associated IDD is mediated by antibody, the immunopathogenicity of MOG antigen is closely related to T cells and B cells. MOG-antibody is sensitive to hormones and has a good prognosis even in the case of multiple relapses.

Key words: Demyelinating diseases, Inflammation, Central nervous system, Antibodies, Magnetic resonance imaging, Recurrence, Glucocorticoids, Child

表1 本组7例MOG抗体相关IDD患儿的临床资料比较

病例(No.)	性别	发病年龄(岁)	感染前驱症状	初始合并症状	发病时诊断	急性期治疗方案	维持治疗方案	ARR(次/年)	随访时间(月)	疗效
1	男	5	有	发热、头痛、视物模糊及眼睛疼痛	ON	甲泼尼龙+IVIG	IVIG+泼尼松	0	16	完全恢复
2	女	5	无	性格改变、头晕及疲劳	脑膜炎	地塞米松+IVIG	IVIG+泼尼松	1	37	部分恢复
3	男	12	无	右手小指、无名指肌无力，右手腕部肌无力	ADEM	地塞米松+IVIG	泼尼松	0	26	完全恢复
4	男	13	有	发热、排尿困难、双下肢运动障碍及疼痛	ADEM	地塞米松+IVIG	泼尼松	0	16	完全恢复
5	女	4	无	反复头痛	MS	地塞米松+IVIG	IVIG+泼尼松	1.4	76	部分恢复
6	男	2	无	反复发热、步态不稳、斜颈、呕吐	AE	地塞米松+IVIG	IVIG+泼尼松	0	15	完全恢复
7	男	7	无	右侧肢体麻木、右下肢轻微跛行、左侧眼睑下垂及视物模糊	ON	地塞米松+IVIG	IVIG+泼尼松	-	1	完全恢复

表1 本组7例MOG抗体相关IDD患儿的临床资料比较

病例(No.)	性别	发病年龄(岁)	感染前驱症状	初始合并症状	发病时诊断	急性期治疗方案	维持治疗方案	ARR(次/年)	随访时间(月)	疗效
1	男	5	有	发热、头痛、视物模糊及眼睛疼痛	ON	甲泼尼龙+IVIG	IVIG+泼尼松	0	16	完全恢复
2	女	5	无	性格改变、头晕及疲劳	脑膜炎	地塞米松+IVIG	IVIG+泼尼松	1	37	部分恢复
3	男	12	无	右手小指、无名指肌无力，右手腕部肌无力	ADEM	地塞米松+IVIG	泼尼松	0	26	完全恢复
4	男	13	有	发热、排尿困难、双下肢运动障碍及疼痛	ADEM	地塞米松+IVIG	泼尼松	0	16	完全恢复
5	女	4	无	反复头痛	MS	地塞米松+IVIG	IVIG+泼尼松	1.4	76	部分恢复
6	男	2	无	反复发热、步态不稳、斜颈、呕吐	AE	地塞米松+IVIG	IVIG+泼尼松	0	15	完全恢复
7	男	7	无	右侧肢体麻木、右下肢轻微跛行、左侧眼睑下垂及视物模糊	ON	地塞米松+IVIG	IVIG+泼尼松	-	1	完全恢复

表2 本组7例MOG抗体相关IDD患儿急性期的神经系统体格检查结果

病例(No.)	视神经	体位、步态	四肢肌力、肌张力	共济运动	深、浅感觉	病理反射	脑膜刺激征
1	视力及视野粗测正常，双侧视盘水肿，双侧眼压增高	正常	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	(—)	(—)
2	视力及视野粗测、眼底均正常	正常	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	双侧巴氏征(+)	颈项强直
3	视力及视野粗测、眼底均正常	正常	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	左侧巴氏征(+)	(—)
4	视力及视野粗测、眼底均正常	呈被动卧位	双上肢肌力正常，双下肢肌力Ⅰ级，四肢肌张力正常	双手指鼻试验、轮替试验可，双侧跟膝胫不能配合	正常	双侧巴氏征(+)	颈稍强直
5	视力及视野粗测、眼底均正常	正常	正常	双手指鼻试验、轮替试验欠佳，双侧跟膝胫对称	正常	双侧巴氏征(+)	(—)
6	视力及视野粗测、眼底均正常	体位正常，步态不稳	正常	双手指鼻试验、轮替试验欠佳，双侧跟膝胫不对称	正常	双侧巴氏征(+)	颈项强直
7	视力及视野粗测正常，左侧视盘水肿，双侧眼压增高	体位正常，右下肢轻微跛行	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	(—)	(—)

表2 本组7例MOG抗体相关IDD患儿急性期的神经系统体格检查结果

病例(No.)	视神经	体位、步态	四肢肌力、肌张力	共济运动	深、浅感觉	病理反射	脑膜刺激征
1	视力及视野粗测正常，双侧视盘水肿，双侧眼压增高	正常	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	(—)	(—)
2	视力及视野粗测、眼底均正常	正常	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	双侧巴氏征(+)	颈项强直
3	视力及视野粗测、眼底均正常	正常	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	左侧巴氏征(+)	(—)
4	视力及视野粗测、眼底均正常	呈被动卧位	双上肢肌力正常，双下肢肌力Ⅰ级，四肢肌张力正常	双手指鼻试验、轮替试验可，双侧跟膝胫不能配合	正常	双侧巴氏征(+)	颈稍强直
5	视力及视野粗测、眼底均正常	正常	正常	双手指鼻试验、轮替试验欠佳，双侧跟膝胫对称	正常	双侧巴氏征(+)	(—)
6	视力及视野粗测、眼底均正常	体位正常，步态不稳	正常	双手指鼻试验、轮替试验欠佳，双侧跟膝胫不对称	正常	双侧巴氏征(+)	颈项强直
7	视力及视野粗测正常，左侧视盘水肿，双侧眼压增高	体位正常，右下肢轻微跛行	正常	双手指鼻试验、轮替试验可，双侧跟膝胫对称	正常	(—)	(—)

表3 本组7例MOG抗体相关IDD患儿脑脊液检查结果

病例(No.)	WBC(×10⁶/L)	红细胞计数(×10⁶/L)	蛋白质含量(g/L)	氯化物浓度(mmol/L)	葡萄糖浓度(mmol/L)	颅内压(mmH₂O)	单纯疱疹病毒	MOG抗体滴度
1	138	141	0.46	124.2	2.8	210	(—)	1∶32
2	9	814	0.13	123.7	2.9	210	(+)	1∶10
3	4	19	0.30	125.7	4.1	150	(—)	1∶10
4	21	15	0.52	123.0	3.4	220	(—)	1∶10
5	5	4	0.31	125.9	4.6	220	(—)	1∶10
6	2 310	9 910	0.17	125.5	3.7	250	(—)	1∶32
7	14	175	0.23	127.4	3.0	250	(—)	(—)

表3 本组7例MOG抗体相关IDD患儿脑脊液检查结果

病例(No.)	WBC(×10⁶/L)	红细胞计数(×10⁶/L)	蛋白质含量(g/L)	氯化物浓度(mmol/L)	葡萄糖浓度(mmol/L)	颅内压(mmH₂O)	单纯疱疹病毒	MOG抗体滴度
1	138	141	0.46	124.2	2.8	210	(—)	1∶32
2	9	814	0.13	123.7	2.9	210	(+)	1∶10
3	4	19	0.30	125.7	4.1	150	(—)	1∶10
4	21	15	0.52	123.0	3.4	220	(—)	1∶10
5	5	4	0.31	125.9	4.6	220	(—)	1∶10
6	2 310	9 910	0.17	125.5	3.7	250	(—)	1∶32
7	14	175	0.23	127.4	3.0	250	(—)	(—)

表4 本组7例MOG抗体相关IDD患儿外周血实验室检查结果

病例(No.)	血常规			感染指标		细胞因子		淋巴细胞亚群(%)			相关抗体
病例(No.)	WBC(×10⁹/L)	中性粒细胞百分比(%)	淋巴细胞百分比(%)	CRP(mg/L)	ESR(mm/h)	IL-6(pg/mL)	IL-8(pg/mL)	CD4⁺	CD8⁺	CD20	MOG	自身免疫性脑炎
1	23.61	85.4	19.3	29.8	100.0	114	50.0	28.5	34.6	18.8	1∶32	—
2	16.50	83.5	23.5	—	88.0	80	220.0	29.3	32.5	26.5	1∶10	—
3	6.75	52.2	35.3	—	35.0	110	59.5	33.4	25.9	22.0	1∶10	—
4	9.51	72.6	18.6	—	63.8	220	77.2	13.5	18.8	55.2	1∶32	—
5	9.02	40.7	49.8	—	27.0	63	221.0	19.1	30.4	26.4	1∶10	—
6	10.74	46.2	38.3	—	10.0	81	243.0	34.7	24.7	19.9	1∶100	抗CASPR-2抗体为1∶30
7	7.01	61.9	31.8	—	10.0	9	235.0	42.0	24.7	15.7	1∶10	—

表4 本组7例MOG抗体相关IDD患儿外周血实验室检查结果

病例(No.)	血常规			感染指标		细胞因子		淋巴细胞亚群(%)			相关抗体
病例(No.)	WBC(×10⁹/L)	中性粒细胞百分比(%)	淋巴细胞百分比(%)	CRP(mg/L)	ESR(mm/h)	IL-6(pg/mL)	IL-8(pg/mL)	CD4⁺	CD8⁺	CD20	MOG	自身免疫性脑炎
1	23.61	85.4	19.3	29.8	100.0	114	50.0	28.5	34.6	18.8	1∶32	—
2	16.50	83.5	23.5	—	88.0	80	220.0	29.3	32.5	26.5	1∶10	—
3	6.75	52.2	35.3	—	35.0	110	59.5	33.4	25.9	22.0	1∶10	—
4	9.51	72.6	18.6	—	63.8	220	77.2	13.5	18.8	55.2	1∶32	—
5	9.02	40.7	49.8	—	27.0	63	221.0	19.1	30.4	26.4	1∶10	—
6	10.74	46.2	38.3	—	10.0	81	243.0	34.7	24.7	19.9	1∶100	抗CASPR-2抗体为1∶30
7	7.01	61.9	31.8	—	10.0	9	235.0	42.0	24.7	15.7	1∶10	—

表5 本组7例MOG抗体相关IDD患儿发病时头颅和脊柱MRI检查结果

病例(No.)	头颅MRI										脊柱MRI
病例(No.)	脑皮质	脑皮质下白质	侧脑室周围白质病变	基底节	丘脑或下丘脑	脑干	小脑	胼胝体	大病灶(>2 cm轴向)	划分界限清晰的病变	延髓受累	颈髓受累	胸髓受累	腰髓受累
1	+	+	—	—	—	—	—	—	+	+	—	—	—	—
2	+	—	+	+	—	+	—	—	+	+	—	—	—	—
3	+	—	+	—	—	—	—	—	+	—	+	+	+	—
4	—	+	—	—	—	—	—	—	+	—	—	+	+	—
5	—	+	+	—	+	—	—	—	+	—	—	—	—	—
6	—	—	+	+	—	—	+	—	+	—	—	—	—	—
7	—	+	+	+	+	—	—	—	+	+	—	—	—	—

表5 本组7例MOG抗体相关IDD患儿发病时头颅和脊柱MRI检查结果

病例(No.)	头颅MRI										脊柱MRI
病例(No.)	脑皮质	脑皮质下白质	侧脑室周围白质病变	基底节	丘脑或下丘脑	脑干	小脑	胼胝体	大病灶(>2 cm轴向)	划分界限清晰的病变	延髓受累	颈髓受累	胸髓受累	腰髓受累
1	+	+	—	—	—	—	—	—	+	+	—	—	—	—
2	+	—	+	+	—	+	—	—	+	+	—	—	—	—
3	+	—	+	—	—	—	—	—	+	—	+	+	+	—
4	—	+	—	—	—	—	—	—	+	—	—	+	+	—
5	—	+	+	—	+	—	—	—	+	—	—	—	—	—
6	—	—	+	+	—	—	+	—	+	—	—	—	—	—
7	—	+	+	+	+	—	—	—	+	+	—	—	—	—

图2 1例MOG抗体相关IDD患儿(No.2，女性，5岁)头颅MRI检查结果(白色箭头示侧脑室后角旁白质多发病灶)

图3 1例MOG抗体相关IDD患儿(No.3，男性，12岁)头颅、全脊柱MRI检查结果[图3A：头颅MRI检查结果(白色箭头示左侧侧脑室后角旁白质及右卵圆中心脑白质异常信号)；图3B：全脊柱MRI检查结果(白色箭头示脊髓内脱髓鞘)]

图4 1例MOG抗体相关IDD患儿(No.4，男，13岁)头颅、全脊柱MRI检查结果[图4A：头颅MRI检查结果(白色箭头示双侧大脑半球皮质下病变)；图4B：全脊柱MRI检查结果(白色箭头示胸段脊髓内病变)]

图6 1例MOG抗体相关IDD患儿(No.6，男性，2岁)头颅常规MRI检查结果(白色箭头示双侧侧脑室旁白质、双侧小脑脚及中脑右部多发异常病变)

图7 1例MOG抗体相关IDD患儿(No.7，男性，7岁)头颅常规MRI检查结果[图7A：头颅MRI横断面(白色箭头示左侧基底节区异常信号)；图7B：头颅MRI冠状面(白色箭头示左侧中脑异常信号)]

[1]	Mayer MC, Breithaupt C, Reindl M, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases[J]. J Immunol, 2013, 191(7): 3594-3604. DOI: 10.4049/jimmunol.1301296.
[2]	Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination[J]. J Neurol Neurosurg Psychiatry, 2018, 89(2): 127-137. DOI: 10.1136/jnnp-2017-316880.
[3]	Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease[J]. Nat Rev Neurol, 2019, 15(2): 89-102. DOI: 10.1038/s41582-018-0112-x.
[4]	Baumann M, Grams A, Djurdjevic T, et al. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein[J]. J Neurol, 2018, 265(4): 845-855. DOI: 10.1007/s00415-018-8781-3.
[5]	Slavin AJ, Johns TG, Orian JM, et al. Regulation of myelin oligodendrocyte glycoprotein in different species throughout development[J]. Dev Neurosci, 1997, 19(1): 69-78. DOI: 10.1159/000111187.
[6]	Lechner C, Baumann M, Hennes EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8): 897-905. DOI: 10.1136/jnnp-2015-311743.
[7]	Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases[J]. Mult Scler, 2016, 22(14): 1821-1829. DOI: 10.1177/1352458516631038.
[8]	Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis[J]. Brain, 2017, 140(3): 617-627. DOI: 10.1093/brain/aww350.
[9]	Denève M, Biotti D, Patsoura S, et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults[J]. J Neuroradiol, 2019, 46(5): 312-318. DOI: 10.1016/j.neurad.2019.06.001.
[10]	Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing[J]. J Neuroinflamm, 2018, 15(1): 134. DOI: 10.1186/s12974-018-1144-2.
[11]	Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders[J]. J Neuroinflammation, 2011, 8: 184. DOI: 10.1186/1742-2094-8-184.
[12]	Di Pauli F, Berger T. Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders？[J]. Front Immunol, 2018, 9: 2753. DOI: 10.3389/fimmu.2018.02753.
[13]	Spadaro M, Winklmeier S, Beltrán E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein[J]. Ann Neurol, 2018, 84(2): 315-328. DOI: 10.1002/ana.25291.
[14]	Horellou P, Wang M, Keo V, et al. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis[J]. J Neuroimmunol, 2015, 289: 1-7. DOI: 10.1016/j.jneuroim.2015.10.002.
[15]	Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer[J]. Cytokine Growth Factor Rev, 2011, 22(2): 83-89. DOI: 10.1016/j.cytogfr.2011.02.003.
[16]	Dale RC, Morovat A. Interleukin-6 and oligoclonal IgG synthesis in children with acute disseminated encephalomyelitis[J]. Neuropediatrics, 2003, 34(3): 141-145. DOI: 10.1055/s-2003-41281.
[17]	Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation[J]. J Exp Med, 2005, 201(2): 233-240. DOI: 10.1084/jem.20041257.
[18]	Bettelli E, Baeten D, Jäger A, et al. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a devic-like disease in mice[J]. J Clin Invest, 2006, 116(9): 2393-2402. DOI: 10.1172/JCI28334.
[19]	Patakas A, Benson RA, Withers DR, et al. Th17 effector cells support B cell responses outside of germinal centres[J]. PLoS One, 2012, 7(11): e49715. DOI: 10.1371/journal.pone.0049715.
[20]	Mitsdoerffer M, Lee Y, Jäger A, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers[J]. Proc Natl Acad Sci USA, 2010, 107(32): 14292-14297. DOI: 10.1073/pnas.1009234107.
[21]	Zhou Y, Jia X, Yang H, et al. Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes[J]. Eur J Neurol, 2019, 26(1): 175-183. DOI: 10.1111/ene.13791.
[22]	Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy[J]. Neurol Neuroimmunol Neuroinflamm, 2017, 4(2): e322. DOI: 10.1212/NXI.0000000000000322.
[23]	Hino-fukuyo N, Haginoya K, Nakashima I, et al. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies[J]. Brain Dev, 2015, 37(9): 849-852. DOI: 10.1016/j.braindev.2015.02.006.
[24]	Lopez-chiriboga AS, Majed M, Dubey D, et al.Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders[J]. JAMA Neurol, 2018, 75(11): 1355-1363.

[1]	Hongyu Tao, Jingjing Ye, Jin Yu, Xiuzhen Yang, Jingjing Qian, Bin Xu, Weize Xu, Qiang Shu. Value of contrast transthoracic echocardiography in assessing right-to-left shunt-related diseases in children[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(10): 959-965.
[2]	Liuqing Li, Xiaoxiang Chen, Chengyu Lv. Comparison of total laparoscopic and laparoscopic assisted radical gastrectomy in the treatment of advanced gastric cancer in the near and medium term[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 23-26.
[3]	Shijun Liu, Jie Ma, Lujing Shi. Near-and medium-term follow-up study of complete mesangectomy plus standard D2 radical resection for advanced gastric cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 27-30.
[4]	Jie Zhang, Xiaoxia Luo, Hong Yu. Predictive value of systemic immune inflammation index in patients with acute pancreatitis complicated with organ function impairment[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 68-71.
[5]	Tianwei Xie, Yufan Pang, Li Wu. Effect of different ultrasound-guided ablation on the volume reduction rate and recurrence rate of benign thyroid nodules[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 80-83.
[6]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[7]	Mei Tang, Li Zhou, Cenyue Niu, Xiaotong Zhou, Qian Wang. Clinical significance of ICG fluorescence guided laparoscopic hepatectomy[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 655-658.
[8]	Wei Li, Zijian Song, Yancheng Lai, Rui Zhou, Han Wu, Longxin Deng, Rui Chen. The current state and prospects of artificial intelligence applied to prognosis prediction in prostate cancer patients[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 541-546.
[9]	Dawen Zheng, Jiandong Wang. Research progress in adjuvant diagnosis of gallbladder cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 769-773.
[10]	Yu Gong, Yuan Liao, Mei Shang. Influencing factors and prediction model for recurrence of hepatocellular carcinoma after TACE[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 818-824.
[11]	Zhendong Jiao, Peng Hui, Shangbo Jin. Application of three-dimensional visualization combined with ICG imaging technology in laparoscopic hepatectomy for recurrent hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 859-864.
[12]	Lijun Zhang, Cunjie Sun, Chunfeng Hu, Chong Meng, Hui Zhang. Accuracy of MSCT and DCE-MRI in evaluating preoperative TNM staging of gastric cancer[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 519-523.
[13]	Chen Zhang, Ming Qin, Juan Dong, Yulong Chen. Diagnostic value of ultrasound in ischemic changes of intestinal volvulus in children[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 565-568.
[14]	Jingming Wang, Lei Wang, Xiaoduo Xu, Wenqiang Xing, Zhaoyan Zhang, Weimin Huang. Advances in research of paravertebral muscles of the lumbar spine[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 846-852.
[15]	Zhaorong Guo, Xinguang Wang, Yiqiang Liu, Yingjian He, Lize Wang, Yang Yang, Xing Wang, Wei Cao, Chongshan Gu, Tie Fan, Jinfeng Li, Zhaoqing Fan. Clinicopathologic characteristics and prognostic risk factors of different subtypes of phyllodes tumor of the breast[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 524-532.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export